Annick Goergler

Title: Annick Goergler: Innovator in Medical Treatment

Introduction

Annick Goergler is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of medical treatment through her innovative research and development of novel compounds. With a total of three patents to her name, her work focuses on addressing critical health challenges, particularly in cancer treatment.

Latest Patents

One of her latest patents is titled "Dihydrobenzimidazolones for Medical Treatment." This invention provides selected dihydrobenzimidazolones that bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN). These compounds alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in the breakdown of intrinsic downstream proteins. The disclosed compounds are particularly useful for the treatment of cancer. Another significant patent is for "Spirocyclic Compounds," which also bind to the E3 ligase protein cereblon (CRBN). This invention outlines their use for treating abnormal cellular proliferation and provides compounds that may serve as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

Career Highlights

Throughout her career, Annick has worked with notable companies, including C4 Therapeutics, Inc. Her innovative approach and dedication to research have positioned her as a key figure in the development of therapeutic solutions.

Collaborations

Annick has collaborated with esteemed colleagues such as Roger David Norcross and Fabian Dey, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Annick Goergler's contributions to medical treatment through her patents and collaborations highlight her role as a leading inventor in her field. Her work continues to pave the way for advancements in cancer treatment and beyond.